Merck announced top-line efficacy results from two ongoing pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant (MK-7264), an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough.
Moderna has announced the dosing of the first participant in a phase1 study of mRNA-1273, the company’s mRNA vaccine candidate against the novel coronavirus (SARS-CoV-2).
Pfizer and EMD Serono are set to scrap the phase 3 JAVELIN Head and Neck 100 study as it was found that avelumab in addition to chemoradiotherapy (CRT) is unlikely to deliver the desired result.
Adaptive Phage Therapeutics (APT) said that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the clinical development of PhageBank, a personalized bacteriophage therapeutic for the treatment of MDR and complicated bacterial infections.
Artugen Therapeutics Limited, a Company developing novel live biotherapeutics (LBPs) for patients living with infectious, inflammatory and oncologic diseases announced today the first patient dosed with ART24, the Company’s first clinical product candidate for prevention of recurrence of Clostridium difficile infection (CDI).
Takeda Pharmaceutical said that the phase 3 TOURMALINE-MM2 study evaluating the addition of NINLARO (ixazomib) to lenalidomide and dexamethasone in certain multiple myeloma population could not deliver the desired results.
InMed Pharmaceuticals has completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV).
Kala Pharmaceuticals said that its dry eye disease candidate KPI-121 0.25% has delivered positive results in a phase 3 trial called STRIDE 3.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH). These patients were naïve to eculizumab and ravulizumab.
Harbour BioMed has secured approval from the US Food and Drug Administration (FDA) to move ahead with clinical studies in the US for its anti-CTLA-4 antibody HBM4003 for the treatment of cancer.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.